Literature DB >> 19380561

Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value?

Haruo Watanabe1, Masayuki Kanematsu, Hiroshi Kondo, Satoshi Goshima, Yusuke Tsuge, Minoru Onozuka, Noriyuki Moriyama.   

Abstract

OBJECTIVE: The objective of our study was to evaluate whether diffusion-weighted MRI has supplementary value in the preoperative T staging of urinary bladder cancer.
MATERIALS AND METHODS: Nineteen consecutive patients (18 men and one woman; age range, 55-83 years; mean, 71 years) known to have or suspected of having urinary bladder cancer underwent MRI at our institution. Urinary bladder cancer was pathologically proven in 18 patients. The pathologic stages were T1 in 14 patients, T2 in two, T3 in one, and T4 in one. Three separate MR image sets were retrospectively reviewed by two independent radiologists: unenhanced T1-weighted images (TR/TE, 607/10) and T2-weighted images (TR(eff)/TE(eff), 4,415/100); unenhanced T1-weighted, T2-weighted, and gadolinium-enhanced images (TR/TE, 10/4.2); and unenhanced T1-weighted, T2-weighted, and diffusion-weighted images (TR(eff)/TE(eff), 2,191/69; b factor, 1,000 s/mm(2)). The radiologists, who were blinded to the pathology findings, assigned T stages and confidence levels for tumors of stage T2 or greater. We used pathologic stages documented in the official pathologic reports as the standard of reference. Observer performance was tested using Spearman's rank correlation, the McNemar test, and receiver operating characteristic (ROC) curve analysis.
RESULTS: The correlation between the radiologic and pathologic stages was greater with the diffusion sequence (rho = 0.66) than with the unenhanced (0.62) or gadolinium-enhanced (0.62) sequence (p = 0.34). The sensitivity, specificity, accuracy, and area under the ROC curve for tumors of stage T2 or greater were 80%, 79%, 79%, and 0.71 for the unenhanced sequence; 80%, 79%, 79%, and 0.77 for the gadolinium sequence; and 40%, 93%, 79%, and 0.56 for the diffusion-weighted sequence, respectively (p > 0.05).
CONCLUSION: Our results suggest that diffusion-weighted MRI might have high specificity for the detection of invasive urinary bladder tumors. Patients with suspected urinary bladder carcinomas may well be evaluated by MRI including diffusion-weighted imaging for better preoperative T staging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380561     DOI: 10.2214/AJR.08.1430

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  16 in total

Review 1.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

2.  Comparison of Coregistration Accuracy of Pelvic Structures Between Sequential and Simultaneous Imaging During Hybrid PET/MRI in Patients with Bladder Cancer.

Authors:  Andrew B Rosenkrantz; Arjun V Balar; William C Huang; Kimberly Jackson; Kent P Friedman
Journal:  Clin Nucl Med       Date:  2015-08       Impact factor: 7.794

3.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

Review 4.  Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract.

Authors:  Alberto Diaz de Leon; Daniel Costa; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

Review 5.  DW-MRI of the urogenital tract: applications in oncology.

Authors:  G Petralia; H C Thoeny
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

6.  PET/CT and MRI in Bladder Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  J Cancer Sci Ther       Date:  2012-07-30

Review 7.  ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Authors:  Leonardo L Monteiro; J Alfred Witjes; Piyush K Agarwal; Christopher B Anderson; Trinity J Bivalacqua; Bernard H Bochner; Joost L Boormans; Sam S Chang; Jose L Domínguez-Escrig; James M McKiernan; Colin Dinney; Guilherme Godoy; Girish S Kulkarni; Paramananthan Mariappan; Michael A O'Donnell; Cyrill A Rentsch; Jay B Shah; Eduardo Solsona; Robert S Svatek; Antoine G van der Heijden; F Johannes P van Valenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2018-08-14       Impact factor: 4.226

8.  Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application.

Authors:  Marwa Makboul; Shimaa Farghaly; Islam F Abdelkawi
Journal:  Br J Radiol       Date:  2019-10-08       Impact factor: 3.039

Review 9.  Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer.

Authors:  Wei-Ching Lin; Jeon-Hor Chen
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243

10.  Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity.

Authors:  Sabina Sevcenco; Andrea Haitel; Lothar Ponhold; Martin Susani; Harun Fajkovic; Shahrokh F Shariat; Manuela Hiess; Claudio Spick; Tibor Szarvas; Pascal A T Baltzer
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.